Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1)
- Target
- KLRG1
- Molecular classification
- Receptor, C-type lectin-like domain receptor, Type II transmembrane glycoprotein, Immune checkpoint receptor
01
Overview
Killer cell lectin-like receptor subfamily G member 1 (KLRG1) is a lymphocyte co-inhibitory receptor, primarily expressed on late-differentiated effector and effector memory CD8+ T cells and natural killer (NK) cells. It acts as an inhibitory receptor that regulates the cytolytic activity of NK cells and modulates both innate and adaptive immune responses by inhibiting proliferation of activated T lymphocytes and reducing NK cell effector function. KLRG1 ligands include E-cadherin and N-cadherin. It is considered a marker of cellular senescence or terminal differentiation in T cells.
- Other names
- 2F1CLEC15AMAFAMAFA-2F1MAFA-LMAFA-LIKE
02
Mechanism of action
Ligand engagement leads to ITIM phosphorylation and recruitment of phosphatases (SHP-2, SHIP-1) to mediate inhibitory signaling.
03
Biological functions
Immune responseRegulation of cytolytic activityInhibition of T lymphocyte proliferationModulation of NK cell effector functionCellular senescence marker
04
Disease associations
CancerInfection
05
Safety considerations
Modulating late-stage immune responses may have implications for autoimmunityReversing terminal differentiation/senescence phenotypes in cytotoxic lymphocytes might lead to uncontrolled proliferation
06
Biomarkers
Marker for late-differentiated/effector/memory CD8+ T lymphocytesMarker for senescent immune subsets
Beyond the preview
Go deeper on Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1).